Performance of CAST (Cellular Antigen Stimulation Test) in Patients With Wasp Venom Allergy: Evaluation of Neutralizing IgG Subclasses

This study is not yet open for participant recruitment.

Verified by University of Zurich, December 2008

Sponsored by:	University of Zurich
Information provided by:	University of Zurich
ClinicalTrials.gov Identifier:	NCT00794287

Purpose

To determine which subclass of IgG in the serum of patients undergoing SIT against wasp venom is able to neutralize the allergen, and therefore to prevent a positive CAST

Condition	Intervention
Wasp Venom Allergic Patients	Other: Taking blood samples

MedlinePlus related topics: Allergy

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Retrospective
Official Title:	Performance of CAST (Cellular Antigen Stiumulation Test)in Patients With Wasp Venom Allergy. Evaluation of Neutralizing IgG Subclasses

Further study details as provided by University of Zurich:

Biospecimen Retention: Samples Without DNA

Biospecimen Description:

Blood samples

Estimated Enrollment:	20
Study Start Date:	January 2009
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
1 Hymenoptera allergic patients before allergen specific immunotherapy	Other: Taking blood samples No intervention is done. Only blood samples are taken.
2 Hymenoptera allergic patients after allergen specific immunotherapy	Other: Taking blood samples No intervention is done. Only blood samples are taken.

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Wasp venom allergic patients grade III and IV according to H.L. Müller in the age group of 18-75 years

Criteria

Inclusion criteria:

male and female patient with allergy to wasp venom grade III and IV according to H.L. Müller
18-75 years
planned SIT against wasp venom or finished 5 years SIT against wsp venom (10/10)

Exclusion criteria:

oral corticosteroids
chromogycin
ketotifen
immunosuppressive drugs within the last 2 years

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00794287

Contacts

Contact: 01 Studienregister MasterAdmins

+41 (0)44 255 11 11

Locations

Switzerland

Zurich, Switzerland

Sponsors and Collaborators

University of Zurich

Investigators

Study Director:

01 Studienregister MasterAdmins

UniversitaetsSpital Zuerich

More Information

Responsible Party:	University of Zurich ( PD Dr. Thomas Kündig )
Study ID Numbers:	ZU-AgNT-004
Study First Received:	November 19, 2008
Last Updated:	December 3, 2008
ClinicalTrials.gov Identifier:	NCT00794287
Health Authority:	Switzerland: UZurich

Study placed in the following topic categories:

Hypersensitivity

ClinicalTrials.gov processed this record on January 14, 2009